                         SEQUENCE LISTING

<110>  The Broad Institute, Inc.
       Dana-Farber Cancer Institute, Inc.
 
<120>  TARGETING EGLN1 IN CANCER

<130>  52199-528001WO

<140>  PCT/US19/50516
<141>  2019-09-11

<150>  62/730,315
<151>  2018-09-12

<160>  2     

<170>  PatentIn version 3.5

<210>  1
<211>  19
<212>  RNA
<213>  Artificial

<220>
<223>  Synthetic

<400>  1
caagguacgc aauaacugu                                                    19


<210>  2
<211>  19
<212>  RNA
<213>  Artificial

<220>
<223>  Synthetic

<400>  2
acaguuauug cguaccuug                                                    19


